Lawrence C Long
Overview
Explore the profile of Lawrence C Long including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nichols B, Offorjebe O, Cele R, Shaba F, Balakasi K, Chivwara M, et al.
J Int AIDS Soc
. 2020 Sep;
23(9):e25612.
PMID: 32909387
Introduction: HIV self-testing (HIVST) in outpatient departments (OPD) is a promising strategy for HIV testing in Malawi, given high OPD patient volumes and substantial wait times. To evaluate the relative...
12.
Larson B, Pascoe S, Huber A, Long L, Murphy J, Miot J, et al.
J Int AIDS Soc
. 2020 Jul;
23(7):e25541.
PMID: 32686911
Introduction: South Africa's National Department of Health launched the National Adherence Guidelines for Chronic Diseases in 2015. These guidelines include adherence clubs (AC) and decentralized medication delivery (DMD) as two...
13.
Onoya D, Sineke T, Hendrickson C, Mokhele I, Maskew M, Long L, et al.
BMJ Open
. 2020 Mar;
10(3):e030228.
PMID: 32213514
Objectives: To assess delays to antiretroviral therapy (ART) initiation before and after the Universal Test and Treat (UTT) and the same-day initiation (SDI) of ART policy periods in Johannesburg, South...
14.
Hirasen K, Evans D, Jinga N, Grabe R, Turner J, Mashamaite S, et al.
Patient Prefer Adherence
. 2020 Feb;
14:133-151.
PMID: 32021124
Introduction: The best method to measure adherence to antiretroviral therapy (ART) in resource-limited settings has not yet been established, particularly among adolescents and young adults (AYAs). The use of mobile...
15.
Long L, DAmico V, Frank S
Sci Total Environ
. 2019 Jan;
658:1523-1530.
PMID: 30678010
Trees are important components of urban landscapes because of the ecosystem services they provide. However, the effects of urbanization, particularly high temperatures, can benefit chronic insect pests and threaten ecosystem...
16.
Hendrickson C, Pascoe S, Huber A, Moolla A, Maskew M, Long L, et al.
J Int AIDS Soc
. 2018 Oct;
21(10):e25184.
PMID: 30318848
Introduction: South Africa is moving into a new era of HIV treatment with "treat all" policies where people may be on treatment for most of their lives. We need to...
17.
Onoya D, Hirasen K, van den Berg L, Miot J, Long L, Fox M
Drug Saf
. 2018 Jul;
41(12):1343-1353.
PMID: 30043384
Introduction: Understanding the occurrence of antiretroviral (ARV)-related adverse events (AEs) among patients receiving second-line antiretroviral therapy (ART) is important in preventing switches to more limited and expensive third-line regimens. Objective:...
18.
Stevens W, Gous N, MacLeod W, Long L, Variava E, Martinson N, et al.
J Acquir Immune Defic Syndr
. 2017 May;
76(1):65-73.
PMID: 28542080
Background: Lack of accessible laboratory infrastructure limits HIV antiretroviral therapy (ART) initiation, monitoring, and retention in many resource-limited settings. Point-of-care testing (POCT) is advocated as a mechanism to overcome these...
19.
Long L, Maskew M, Brennan A, Mongwenyana C, Nyoni C, Malete G, et al.
AIDS
. 2017 May;
31(11):1611-1619.
PMID: 28463879
Objective: Determine the cost and cost-effectiveness of single-visit (same-day) antiretroviral treatment (ART) initiation compared to standard of care initiation. Design: Cost-effectiveness analysis of individually randomized (1 : 1) pragmatic trial...
20.
Onoya D, Nattey C, Budgell E, van den Berg L, Maskew M, Evans D, et al.
AIDS Patient Care STDS
. 2017 Apr;
31(5):205-212.
PMID: 28445088
Although third-line antiretroviral therapy (ART) is available in South Africa's public sector, its cost is substantially higher than first and second line. Identifying risk factors for failure on second-line treatment...